Antidepressant Drug Market Heats Up: Some Pharma Companies Expand R&D While Others Divest Projects

　　【Pharmaceutical Network Industry DynamicsDepression is a mental disorder with a high prevalence and a high clinical cure rate. According to data from the World Health Organization, the global incidence of depression is approximately 11%, with about 340 million people suffering from depression worldwide. In China, the number of patients with depression is increasing. Data from the "2022 Blue Book of National Depression" shows that there are currently 95 million people in China suffering from depression, with approximately one in every 14 people being a depression patient. As depression has gradually become scientifically understood in recent years, the treatment rate among domestic patients has been continuously improving, and the market demand for antidepressant drugs has also been expanding, leading to continuous growth in the scale of the entire industry's market. Data shows that the size of China’s antidepressant drug market reached 18.41 billion yuan in 2022 and is expected to reach 23.8 billion yuan by 2030.
 

Facing a market potential of tens of billions, pharmaceutical companies in and outside China have been stepping up their efforts in the research and development of antidepressants in recent years. On January 21, Johnson & Johnson, a leading multinational pharmaceutical company, announced that the U.S. FDA had approved its Spravato (esketamine) nasal spray for the treatment of adults with treatment-resistant depression (TRD).
 

It is reported that Spravato is the first monotherapy approved for treating adult patients with major depressive disorder (MDD) who have responded inadequately to at least two oral antidepressants. It is a non-selective, non-competitive NMDA receptor antagonist, which may help repair neuronal connections in brain cells of patients with depression. Trial results showed that Spravato reached the primary endpoint at week 4. Moreover, compared with placebo, it rapidly and significantly improved depressive symptoms in patients as early as within 24 hours.
 

Notably, Johnson & Johnson's ambition in the antidepressant market has become evident this year. On January 13, just a short while ago, Johnson & Johnson announced a major acquisition deal at the J.P. Morgan Healthcare Conference (hereinafter referred to as "JPM Conference"). The company will acquire Intra-Cellular Therapies for $14.6 billion through a combination of cash and debt, marking its entry into the neuroscience field. Through this acquisition, Johnson & Johnson will gain access to Caplyta (lumateperone), a once-daily oral therapy approved for treating adult schizophrenia and depressive episodes associated with bipolar I or II disorder. The acquisition also includes ITI-1284, a compound currently in Phase II research, which is being studied for generalized anxiety disorder (GAD) and psychosis related to Alzheimer’s disease.
 

In China, Jiangsu Nhwa Pharmaceutical Co., Ltd. announced on January 20 that the company had recently received the "Drug Registration Certificate" for Vortioxetine Hydrobromide Tablets issued by the National Medical Products Administration, with a specification of 10mg. The drug falls under the registration category of Chemical Drug Class 4 and is indicated for the treatment of adult depression.
 

Nhwa Pharmaceutical stated that obtaining the Drug Registration Certificate for Vortioxetine Hydrobromide Tablets has enriched the company's product pipeline in the central nervous system field, which is beneficial for enhancing the company's market competitiveness. The market launch of this drug will positively impact the company’s future performance.
 

However, drug development is not an easy task. While a group of pharmaceutical companies are stepping up their efforts in the antidepressant market, some companies have decided to transfer their antidepressant R&D projects after considering various factors.
 

For example, on the evening of January 8, Huahai Pharmaceutical Co., Ltd. announced that it had entrusted China Rongtong Science Research Institute Group Co., Ltd. to transfer the patent rights and technical achievements of the antidepressant new drug research and development project - Hydroxypiperylon Hydrochloride Tablets (hereinafter referred to as the "HHT101 Project") through public listing by the China Technology Exchange. It is reported that the proposed transfer transaction reserve price (including upfront payment and milestone payments) for the project is 110 million yuan, plus a 1.5% share of sales revenue after the drug is marketed (to be paid consecutively for 10 years).
 

Regarding the transfer of the HHT101 project this time, Huahai Pharmaceutical stated that it aims to further integrate the company's R&D resources, improve R&D efficiency, accelerate the realization of R&D value, and continuously enhance the company's sustainable development capabilities to promote high-quality growth.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.